Impaired transmethylation potential in Parkinson's disease patients treated with l-Dopa

Neuroscience Letters

Volumn 468, Issue 3, 2010, Pages 287-291

  De Bonis, Maria Luigia ^a,c   Tessitore, Alessandro ^a   Pellecchia, Maria Teresa ^b   Longo, Katia ^b   Salvatore, Anna ^a   Russo, Antonio ^a   Ingrosso, Diego ^a   Zappia, Vincenzo ^a   Barone, Paolo ^b   Galletti, Patrizia ^a   Tedeschi, Gioacchino ^a,d  

^a SECOND UNIVERSITY OF NAPLES   (Italy)

^b UNIVERSITY OF NAPLES FEDERICO II   (Italy)

^c REFERRAL CANCER CENTER OF BASILICATA   (Italy)

^d Institute Hermitage Capodimonte   (Italy)

Author keywords

COMT; Homocysteine; l Dopa; Methylation; Parkinson's disease; Transmethylation potential

Indexed keywords

5,10 METHYLENETETRAHYDROFOLATE REDUCTASE (FADH2); LEVODOPA; S ADENOSYLHOMOCYSTEINE; S ADENOSYLMETHIONINE;

ADULT; AGED; ARTICLE; CELL LEVEL; CLINICAL ARTICLE; CLINICAL FEATURE; CONTROLLED STUDY; DISEASE DURATION; DISEASE PREDISPOSITION; FEMALE; GENE EXPRESSION; GENE FREQUENCY; GENETIC POLYMORPHISM; GENOTYPE; HOMEOSTASIS; HUMAN; HYPERHOMOCYSTEINEMIA; MALE; METHYLATION; PARKINSON DISEASE; PATHOGENESIS; PRIORITY JOURNAL;

AGED; ANTIPARKINSON AGENTS; CROSS-SECTIONAL STUDIES; ERYTHROCYTES; FEMALE; GENOTYPE; HOMOCYSTEINE; HUMANS; LEVODOPA; MALE; METHYLATION; METHYLENETETRAHYDROFOLATE REDUCTASE (NADPH2); MIDDLE AGED; PARKINSON DISEASE; POLYMORPHISM, GENETIC; S-ADENOSYLHOMOCYSTEINE; S-ADENOSYLMETHIONINE;

EID: 72549098567     PISSN: 03043940     EISSN: None     Source Type: Journal    
DOI: 10.1016/j.neulet.2009.11.014     Document Type: Article

References (24)

1. Banfield K., and Clarke S. In: Chen X., and Blumenthal R.M. (Eds). S-Adenosylmethionine-dependent methyltransferases: structures and functions (1999), World Scientific, London 123-140
2. Barone P., Burn D.J., van Laar T., Hsu C., Poewe W., and Lane R.M. Rivastigmine versus placebo in hyperhomocysteinemic Parkinson's disease dementia patients. Mov. Disord. 23 (2008) 1532-1540
3. Camicioli R.M., Bouchard T.P., and Somerville M.J. Homocysteine is not associated with global motor or cognitive measures in nondemented older Parkinson's disease patients. Mov. Disord. 24 (2009) 176-182
4. Chambers J.C., McGregor A., Jeff J.M., and Kooner J.S. Acute hyperhomocysteinaemia and endothelial dysfunction. Lancet 351 (1998) 36-37
5. Cheng H., Gomes-Trolin C., Aquilonius S.M., Steinberg A., Löfberg C., Ekblom J., and Oreland L. Levels of l-methionine S-adenosyltransferase activity in erythrocytes and concentrations of S-adenosylmethionine and S-adenosylhomocysteine in whole blood of patients with Parkinson's disease. Exp. Neurol. 145 (1997) 580-585
6. Christopher R., Nagaraja D., and Shankar S.K. Homocysteine and cerebral stroke in developing countries. Curr. Med. Chem. 14 (2007) 2393-2401
7. Frosst P., Blom H.J., Milos R., Goyette P., Sheppard C.A., Matthews R.G., Boers G.J., den Heijer M., Kluijtmans L.A., van den Heuvel L.P., and Rozen R. A candidate genetic risk factor for vascular disease: a common mutation in methylenetetrahydrofolate reductase. Nat. Genet. 10 (1995) 111-113
8. Galletti P., De Bonis M.L., Sorrentino A., Raimo M., D'Angelo S., Scala I., Andria G., D'Aniello A., Ingrosso D., and Zappia V. Accumulation of altered aspartyl residues in erythrocyte proteins from patients with Down's syndrome. FEBS J. 274 (2007) 5263-5277
9. Hughes A.J., Daniel S.E., Kilford L., and Lees A.J. Accuracy of clinical diagnosis of idiopathic Parkinson's disease: a clinico-pathological study of 100 cases. J. Neurol. Neurosurg. Psychiatry 55 3 (1992) 181-184
10. Klerk M., Verhoef P., larke R., Blom H.J., Kok F.J., and Schouten E.G. MTHFR 677C→T polymorphism and risk of coronary heart disease: a meta-analysis. JAMA 288 (2002) 2023-2031
11. Kruman I.I., Culmsee C., Chan S.L., Kruman Y., Guo Z., Penix L., and Mattson M.P. Homocysteine elicits a DNA damage response in neurons that promotes apoptosis and hypersensitivity to excitotoxicity. J. Neurosci. 20 (2000) 6920-6926
12. Nutt J.G. Pharmacokinetics and pharmacodynamics of levodopa. Mov. Disord. 23 Suppl. 3 (2008) S580-S584
13. O'Suilleabhain P.E., Sung V., Hernandez C., Lacritz L., Dewey Jr. R.B., Bottiglieri T., and Diaz-Arrastia R. Elevated plasma homocysteine level in patients with Parkinson disease: motor, affective, and cognitive associations. Arch. Neurol. 61 (2004) 865-868
14. Perna A.F., Ingrosso D., Galletti P., Zappia V., and De Santo N.G. Membrane protein damage and methylation reactions in chronic renal failure. Kidney Int. 50 (1996) 358-366
15. Postuma R.B., and Lang A.E. Homocysteine and levodopa: should Parkinson disease patients receive preventive therapy?. Neurology 63 (2004) 886-891
16. Religa D., Czyzewski K., Styczynska M., Peplonska B., Lokk J., Chodakowska-Zebrowska K., Stepien B., Winblad M., and Barcikowska. Hyperhomocysteinemia and methylenetetrahydrofolate reductase polymorphism in patients with Parkinson's disease. Neurosci. Lett. 404 (2006) 56-60
17. Rogers J.D., Sanchez-Saffon A., Frol A.B., and Diaz-Arrastia R. Elevated plasma homocysteine levels in patients treated with levodopa: association with vascular disease. Arch. Neurol. 60 (2003) 59-64
18. Seshadri S., Beiser A., Selhub J., Jacques P.F., Rosemberg I.H., D'Agostino R.B., Wilson P.W.F., and Wolf P.A. Plasma homocysteine as a risk factor for dementia and Alzheimer's disease. N. Engl. J. Med. 346 (2002) 476-483
19. Todorovic Z., Dzoljic E., Novakovic I., Mirkovic D., Stojanovic R., Nesic Z., Krajinovic M., Prostran M., and Kostic V. Homocysteine serum levels and MTHFR C677T genotype in patients with Parkinson's disease, with and without levodopa therapy. J. Neurol. Sci. 248 (2006) 56-61
20. Yasui K., Nakaso K., Kowa H., Takeshima T., and Nakashima K. Levodopa-induced hyperhomocysteinaemia in Parkinson's disease. Acta Neurol. Scand. 108 (2003) 66-67
21. Zhao W.Q., Latinwo L., Liu X.X., Lee E.S., Lamango N., and Charlton C.G. l-Dopa upregulates the expression and activities of methionine adenosyl transferase and catechol-O-methyltransferase. Exp. Neurol. 171 (2001) 127-138
22. Zoccolella S., dell'Aquila C., Abruzzese G., Antonini A., Bonuccelli U., Canesi M., Cristina S., Marchese R., Pacchetti C., Zagaglia R., Logroscino G., Defazio G., Lamberti P., and Livrea P. Hyperhomocysteinemia in levodopa-treated patients with Parkinson's disease dementia. Mov. Disord. 24 (2009) 1028-1033
23. Zoccolella S., Lamberti P., Armenise E., de Mari M., Lamberti S.V., Mastronardi R., Fraddosio A., Iliceto G., and Livrea P. Plasma homocysteine levels in Parkinson's disease: role of antiparkinsonian medications. Park. Rel. Dis. 11 (2005) 131-133
24. Zoccolella S., Lamberti P., Iliceto G., dell'Aquila C., Diroma C., Fraddosio A., Lamberti S.V., Armenise E., Defazio G., de Mari M., and Livrea P. Elevated plasma homocysteine levels in l-Dopa-treated Parkinson's disease patients with dyskinesias. Clin. Chem. Lab. Med. 44 (2006) 863-866